UK study depicts successful biotechnology sector:
This article was originally published in Clinica
The UK biotechnology sector is booming, says a new report by consultants Arthur Andersen. The study shows that the number of biotech companies in the UK has increased 32% since 1994 to 221 in 1997. This figure is expected to grow by a further 30% to nearly 300 by the end of 1998. Copies of Arthur Andersen's UK biotech 97 - making the right moves are available from Jackie Morgan, Tel: 0171 438 5243. Fax: 0171 438 5246.
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.